ExpreS2ion Biotech Holding AB Asset Resilience Ratio
ExpreS2ion Biotech Holding AB asset resilience ratio. ExpreS2ion Biotech Holding AB (EXPRS2) has an Asset Resilience Ratio of 5.64% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ExpreS2ion Biotech Holding AB defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ExpreS2ion Biotech Holding AB (2018–2023)
Asset resilience ratio of ExpreS2ion Biotech Holding AB from 2018 to 2023. This chart shows how ExpreS2ion Biotech Holding AB's Asset Resilience Ratio has changed over time. Read ExpreS2ion Biotech Holding AB total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ExpreS2ion Biotech Holding AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ExpreS2ion Biotech Holding AB asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr4.44 Million | 5.64% |
| Total Liquid Assets | Skr4.44 Million | 5.64% |
Asset Resilience Insights
- Limited Liquidity: ExpreS2ion Biotech Holding AB maintains only 5.64% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ExpreS2ion Biotech Holding AB Industry Peers by Asset Resilience Ratio
Compare ExpreS2ion Biotech Holding AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
ExpreS2ion Biotech Holding AB Asset Resilience Ratio by Year (2018–2023)
ExpreS2ion Biotech Holding AB asset resilience ratio by year from 2018 to 2023. The table below shows the annual Asset Resilience Ratio data for ExpreS2ion Biotech Holding AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 5.64% | Skr4.44 Million ≈ $477.49K |
Skr78.69 Million ≈ $8.47 Million |
+6.75pp |
| 2022-12-31 | -1.12% | Skr-1.53 Million ≈ $-164.87K |
Skr137.36 Million ≈ $14.78 Million |
-68.09pp |
| 2021-12-31 | 66.97% | Skr101.77 Million ≈ $10.95 Million |
Skr151.96 Million ≈ $16.35 Million |
+67.79pp |
| 2020-12-31 | -0.81% | Skr-966.00K ≈ $-103.96K |
Skr118.86 Million ≈ $12.79 Million |
+4.17pp |
| 2019-12-31 | -4.99% | Skr-933.00K ≈ $-100.41K |
Skr18.71 Million ≈ $2.01 Million |
-1.73pp |
| 2018-12-31 | -3.25% | Skr-682.00K ≈ $-73.39K |
Skr20.95 Million ≈ $2.25 Million |
-- |
About ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company's lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vacci… Read more